Risk factors for immune checkpoint inhibitor pneumonitis

Type of malignancy

Non-small cell lung cancer (squamous cell carcinoma at higher risk than non-squamous cell carcinoma of the lung)
Renal cell carcinoma

ICI regimen

Combination immunotherapy (eg, CTLA-4 inhibitor plus PD-L1 inhibitor) carries a higher risk than single-agent immunotherapy (eg, PD-1 or PD-L1 inhibitors)

Pre-existing interstitial lung abnormality or confirmed interstitial lung disease

Chronic lung disease (eg, chronic obstructive pulmonary disease, asthma)

Smoking or tobacco use

Autoimmune disease

Prior curative-intent radiation therapy to the lungs

Male sex

CTLA-4: cytotoxic T lymphocyte-associated antigen 4; ICI: immune checkpoint inhibitor; PD-1: programmed cell death receptor 1; PD-L1: programmed cell death ligand 1.

References:

Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017; 10:50.
Tiu BC, Zubiri L, Iheke J, et al. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: A multi-institutional cohort study. J Immunother Cancer 2022; 10:e00460.
Atchley W, Alvarez C, Saxena-Beem S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: Real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest 2021; 160:731.

Graphic 145876 Version 1.0

خرید پکیج

Risk factors for immune checkpoint inhibitor pneumonitis